Phase 3 Readout~month
Phase 3 Topline: A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PI
- Company
- Ocugen, Inc. (OCGN)
- Indication
- Stargardt Disease
Other upcoming events for OCGN
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.